Organs-on-chips
Organs-on-chips now have a clearer way into drug-safety testing. The US Food and Drug Administration's September 2026 rulemaking recognises suitable non-animal methods. It does not lower evidence standards or abolish animal studies. Companies still have to validate a model for a particular regulatory question, and a more realistic model is not enough.
Research snapshot · updated Nov 12, 2026
Core thesis
Organs-on-chips model drug metabolism, toxicity, and efficacy using human cells under physiological flow. Emulate (co-founded by Donald Ingber) remains the reference platform vendor. The regulatory pull is no longer just the FDA Modernization Act 2.0 (2022): the FDA published its Roadmap to Reducing Animal Testing in April 2025, reported meeting year-one goals in April 2026, and the FDA Modernization Act 3.0 cleared the Senate in December 2025. Adoption is real but still mostly supplements rather than replaces animal models; reproducibility and thin platform revenue keep it a slow burn.
State of the art (2026)
The regulatory tailwind is now concrete rather than aspirational. The FDA published its Roadmap to Reducing Animal Testing in April 2025 and reported meeting year-one goals in early 2026, with draft guidance (December 2025) on cutting non-human-primate studies for monoclonal antibodies. The Senate passed the FDA Modernization Act 3.0 by unanimous consent in December 2025; the House version cleared committee in May 2026, which would force the FDA to rewrite IND rules to recognise non-animal data. Commercially the field is still small (roughly $390M in 2025) and consolidating: Emulate launched its 96-chip AVA high-throughput system in June 2025 and showcased it at SLAS2026, while Hesperos folded into Javelin Biotech. Liver and gut chips lead on validation; multi-organ body-on-chip reproducibility is what still blocks routine pharma use.
Explore the deeper analysis in CanaryIQ
Explore what is covered below. These previews show the structure; log in to read the full analysis.
Signal stack
Evidence stacked leading → lagging
10 signals
Signal stack
Evidence stacked leading → lagging
Technology-native KPIs
Metrics that predict trajectory, tracked over time
4 tracked
Technology-native KPIs
Metrics that predict trajectory, tracked over time
Landscape map
Who builds what, and who depends on whom
167 players · 6 layers
Landscape map
Who builds what, and who depends on whom
Catalyst calendar
Dated events that will move the position
3 ahead
Catalyst calendar
Dated events that will move the position
Technology roadmap
Milestones on the path to maturity
6 milestones
Technology roadmap
Milestones on the path to maturity
Watchlists
Companies, people and papers, each with a condition for removing it
20 · 2
Watchlists
Companies, people and papers, each with a condition for removing it
Decision frameworks
What our view means for your job
Locked
Decision frameworks
What our view means for your job
Thesis changelog
When our view changed, and why
7 updates
Thesis changelog
When our view changed, and why
Change our mind
3 disconfirming conditions
You've read the verdict. The file is much deeper.
The full signal stack, technology-native KPIs tracked over time, the landscape of who depends on whom, the dated catalyst calendar, decision frameworks for every desk, live watchlists and a record of every time our view on Organs-on-chips has changed. All of it is in CanaryIQ.